Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing

  title={Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing},
  author={Volker Hovestadt and David T. W. Jones and Simone Picelli and Wei Wang and Marcel Kool and Paul A. Northcott and Marc Sultan and Katharina Stachurski and Marina Ryzhova and Hans-J{\"o}rg Warnatz and Meryem Ralser and Sonja Brun and Jens Bunt and Natalie J{\"a}ger and Kortine Kleinheinz and Serap Erkek and Ursula D. Weber and Cynthia C. Bartholomae and Christof von Kalle and Chris Lawerenz and J{\"u}rgen Eils and Jan Koster and Rogier Versteeg and Till Milde and Olaf Witt and Sabine S. Schmidt and Stephan Wolf and Torsten Pietsch and Stefan Rutkowski and Wolfram G. Scheurlen and Michael D. Taylor and Benedikt Brors and Joerg Felsberg and Guido Reifenberger and Arndt Borkhardt and Hans Lehrach and Robert J Wechsler-Reya and Roland Eils and Marie-Laure Yaspo and Pablo Landgraf and Andrey Korshunov and Marc Zapatka and Bernhard Radlwimmer and Stefan M. Pfister and Peter Lichter},
Epigenetic alterations, that is, disruption of DNA methylation and chromatin architecture, are now acknowledged as a universal feature of tumorigenesis. Medulloblastoma, a clinically challenging, malignant childhood brain tumour, is no exception. Despite much progress from recent genomics studies, with recurrent changes identified in each of the four distinct tumour subgroups (WNT-pathway-activated, SHH-pathway-activated, and the less-well-characterized Group 3 and Group 4), many cases still… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 56 times over the past 90 days. VIEW TWEETS